CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.72−0.02 (-2.35%)
Close on Oct 19, 2026
- Market cap
- $2.68M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.8664 (−79.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. saw revenue fall 50.0% to $3.00K over the twelve months to Jun 30, 2026.
Revenue
$3.00K
-50.0% vs. a year earlier
Operating income
-$6.24M
TTM Q2 2026
EPS, diluted
-$1.97
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.68M
- P/E ratio
- –
- Price to sales
- 892.84
- Price to book
- 0.31
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.00K
- Net income
- -$6.04M
- EPS, diluted
- -$1.97
- Book value per share
- $2.34
- Diluted shares
- 4M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.00K-50.0% YoY
Gross profit
$2.01K-44.3% YoY
Operating income
-$6.24M
Net income
-$6.04M
EPS, diluted
-$1.97
Reported periodTrailing twelve months